Leading the Way in Inhalation Science: Daniela Traini to Keynote at SMI London 2025
Watch the Fireside chat on SMI development with Daniela and Philippe
We are proud to share that Professor Daniela Traini, Chief Scientific Officer at Ab Initio Pharma and Professor of Respiratory Science at Macquarie University, will be the keynote speaker at SMI.London 2025 on June 25th. As one of the foremost experts in respiratory drug delivery, Prof. Traini brings over two decades of research leadership across academia and industry.
In a recent pre-conference interview, Prof. Traini discussed the evolving role of soft mist inhalers (SMIs) and their potential to transform drug delivery—not only for traditional respiratory conditions like asthma and COPD, but also for systemic, neurological, and gene therapies. Her insights reflect a global shift in how we approach the lung and nasal pathways: not just as targets for local treatment, but as portals for precise, patient-friendly systemic delivery.
At Ab Initio Pharma, we share this vision. As a CDMO specialising in complex inhalation dosage forms,, we offer GMP-certified development and manufacturing capabilities to take innovative respiratory products from bench to clinic. Our team brings extensive expertise in formulation science, analytical method development, and regulatory strategy—empowering clients to accelerate their pipelines with confidence.
Prof. Traini's keynote will highlight her recent work on SMI compatibility with biologics such as lipid nanoparticles and RNA-based therapies, reaffirming the device’s unique suitability for next-generation medicines. As she emphasized, SMIs are "gentle on fragile molecules" and ideally suited for immunotherapy, gene delivery, and pediatric and geriatric populations….areas of growing focus for Ab Initio and our partners.
We look forward to joining the global community at SMI.London 2025 and invite you to connect with us there. To learn more about how Ab Initio can support your inhalation product development, visit www.abinitiopharma.com.
